FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387307934> ?p ?o ?g. }

• W4387307934 abstract "Background Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without brain metastases (BM). To inform clinical decision-making, it is important to understand tucatinib use in real-world clinical practice. We describe patient characteristics, treatment patterns, and clinical outcomes for tucatinib treatment in the real-world setting. Methods This retrospective cohort study included patients diagnosed with HER2+ MBC (January 2017-December 2022) who received tucatinib treatment in a nationwide, de-identified electronic health record–derived metastatic breast cancer database. Patient demographics and clinical characteristics were described at baseline (prior to tucatinib initiation). Key outcomes included real-world time to treatment discontinuation (rwTTD), time to next treatment (rwTTNT), and overall survival (rwOS). Results Of 3,449 patients with HER2+ MBC, 216 received tucatinib treatment (n=153 with BM; n=63 without BM) and met inclusion criteria. Median (range) age of patients was 56 (28-84) years, 57.9% were White, and 68.5% had Eastern Cooperative Oncology Group performance status ≤1. Median (IQR) follow-up from start of tucatinib treatment was 12 (6-18) months. Among all patients who received tucatinib treatment, median (95% CI) rwTTD was 6.5 (5.4-8.8) months with 39.8% and 21.4% remaining on treatment at 12 and 24 months, respectively. Median (95% CI) rwTTNT was 8.7 (6.8-10.7) months. Patients who received the approved tucatinib triplet combination after ≥1 HER2-directed regimen in the metastatic setting had a similar median (95% CI) rwTTD (any line: 8.1 [5.7-9.5] months; second-line (2L) and third-line (3L): 9.4 [6.3-14.1] months) and rwTTNT (any line: 8.8 [7.1-11.8] months; 2L and 3L: 9.8 [6.8-14.1] months) to the overall population. Overall, median (95% CI) rwOS was 26.6 (20.2-not reached [NR]) months, with similar findings for patients who received the tucatinib triplet (26.1 [18.8-NR] months) and was NR in the subgroup limited to the 2L/3L population. Conclusion Tucatinib treatment in the real-world setting was associated with a similar median rwTTD, rwTTNT, and rwOS as in the pivotal HER2CLIMB trial, with particular effectiveness in patients in the 2L/3L setting. These results highlight the importance of earlier use of tucatinib in HER2+ MBC." @default.
• W4387307934 created "2023-10-04" @default.
• W4387307934 creator A5011894823 @default.
• W4387307934 creator A5013557141 @default.
• W4387307934 creator A5014192243 @default.
• W4387307934 creator A5020203591 @default.
• W4387307934 creator A5027346001 @default.
• W4387307934 creator A5047262526 @default.
• W4387307934 creator A5050118261 @default.
• W4387307934 creator A5056473602 @default.
• W4387307934 creator A5057404007 @default.
• W4387307934 creator A5061684415 @default.
• W4387307934 creator A5090946504 @default.
• W4387307934 date "2023-10-02" @default.
• W4387307934 modified "2023-10-05" @default.
• W4387307934 title "Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer" @default.
• W4387307934 cites W2071188109 @default.
• W4387307934 cites W2130735457 @default.
• W4387307934 cites W2179942617 @default.
• W4387307934 cites W2395095892 @default.
• W4387307934 cites W2417688627 @default.
• W4387307934 cites W2560406314 @default.
• W4387307934 cites W2571057012 @default.
• W4387307934 cites W2600385000 @default.
• W4387307934 cites W2616160160 @default.
• W4387307934 cites W2902270791 @default.
• W4387307934 cites W2907345836 @default.
• W4387307934 cites W2995808512 @default.
• W4387307934 cites W3000283591 @default.
• W4387307934 cites W3011119029 @default.
• W4387307934 cites W3032024065 @default.
• W4387307934 cites W3049212519 @default.
• W4387307934 cites W3085274530 @default.
• W4387307934 cites W3128646645 @default.
• W4387307934 cites W3180426532 @default.
• W4387307934 cites W3207557929 @default.
• W4387307934 cites W4226051140 @default.
• W4387307934 cites W4281675214 @default.
• W4387307934 cites W4281757801 @default.
• W4387307934 doi "https://doi.org/10.3389/fonc.2023.1264861" @default.
• W4387307934 hasPublicationYear "2023" @default.
• W4387307934 type Work @default.
• W4387307934 citedByCount "0" @default.
• W4387307934 crossrefType "journal-article" @default.
• W4387307934 hasAuthorship W4387307934A5011894823 @default.
• W4387307934 hasAuthorship W4387307934A5013557141 @default.
• W4387307934 hasAuthorship W4387307934A5014192243 @default.
• W4387307934 hasAuthorship W4387307934A5020203591 @default.
• W4387307934 hasAuthorship W4387307934A5027346001 @default.
• W4387307934 hasAuthorship W4387307934A5047262526 @default.
• W4387307934 hasAuthorship W4387307934A5050118261 @default.
• W4387307934 hasAuthorship W4387307934A5056473602 @default.
• W4387307934 hasAuthorship W4387307934A5057404007 @default.
• W4387307934 hasAuthorship W4387307934A5061684415 @default.
• W4387307934 hasAuthorship W4387307934A5090946504 @default.
• W4387307934 hasBestOaLocation W43873079341 @default.
• W4387307934 hasConcept C121608353 @default.
• W4387307934 hasConcept C126322002 @default.
• W4387307934 hasConcept C143998085 @default.
• W4387307934 hasConcept C2775930923 @default.
• W4387307934 hasConcept C2777909004 @default.
• W4387307934 hasConcept C2778715236 @default.
• W4387307934 hasConcept C526805850 @default.
• W4387307934 hasConcept C530470458 @default.
• W4387307934 hasConcept C71924100 @default.
• W4387307934 hasConceptScore W4387307934C121608353 @default.
• W4387307934 hasConceptScore W4387307934C126322002 @default.
• W4387307934 hasConceptScore W4387307934C143998085 @default.
• W4387307934 hasConceptScore W4387307934C2775930923 @default.
• W4387307934 hasConceptScore W4387307934C2777909004 @default.
• W4387307934 hasConceptScore W4387307934C2778715236 @default.
• W4387307934 hasConceptScore W4387307934C526805850 @default.
• W4387307934 hasConceptScore W4387307934C530470458 @default.
• W4387307934 hasConceptScore W4387307934C71924100 @default.
• W4387307934 hasFunder F4320319515 @default.
• W4387307934 hasLocation W43873079341 @default.
• W4387307934 hasOpenAccess W4387307934 @default.
• W4387307934 hasPrimaryLocation W43873079341 @default.
• W4387307934 hasRelatedWork W192535437 @default.
• W4387307934 hasRelatedWork W2072467807 @default.
• W4387307934 hasRelatedWork W2092651826 @default.
• W4387307934 hasRelatedWork W2382613782 @default.
• W4387307934 hasRelatedWork W2762232864 @default.
• W4387307934 hasRelatedWork W3031563781 @default.
• W4387307934 hasRelatedWork W4224439900 @default.
• W4387307934 hasRelatedWork W4233817077 @default.
• W4387307934 hasRelatedWork W4250720993 @default.
• W4387307934 hasRelatedWork W4362586374 @default.
• W4387307934 hasVolume "13" @default.
• W4387307934 isParatext "false" @default.
• W4387307934 isRetracted "false" @default.
• W4387307934 workType "article" @default.